Three Surgeons In East Texas Are Successfully Integrating A Novel Stem Cell Procedure For Spine Surgeries
A new breakthrough in adult stem cell technology has three Texarkana neurosurgeons leading their industry by utilizing concentrated stem cells for spine surgery. The innovative technique is improving the desired results of surgical interventions for back pain. Leading researchers in the orthopedic and spine industry are predicting the latest developments in this field of medicine will become mainstream practice and, potentially, a standard of care for surgical treatments of severe back pain.
Nutrition
Pages: 1 [2]
Sanofi-aventis And Regeneron Announce Results From Phase 2 Study With Aflibercept (VEGF Trap) In Advanced Ovarian Cancer
in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMEA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis" annual report on Form 20-F for the year ended December 31, 2008. Other than as required by applicable law, sanofiaventis does not undertake any obligation to update or revise any forward-looking information or statements. Forward Looking Statements - Regeneron Pharmaceuticals, Inc. This news release discusses historical information and includes forward-looking statements about Regeneron and its products, development programs, finances, and business, all of which involve a number of risks and uncertainties, such as risks associated with preclinical and clinical development of aflibercept, determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron"s ability to continue to develop or commercialize aflibercept, competing drugs that are superior to aflibercept, uncertainty of market acceptance of aflibercept, the potential for any collaboration agreement, including Regeneron"s agreements with the sanofi-aventis Group and Bayer HealthCare, to be canceled or to terminate without any product success, risks associated with third party intellectual property, and other material risks. A more complete description of these and other material risks can be found in Regeneron"s filings with the United States Securities and Exchange Commission (SEC), including its Form 10-K for the year ended December 31, 2008 and Form 10-Q for the quarter ending March 31, 2009. Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise unless required by law. Sanofi AventisPages: 1 [2]